Semper paratus

Semper Paratus Acquisition Corporation’s Shareholders Approve Business Combination with Tevogen Bio

Retrieved on: 
Thursday, February 1, 2024
Accounting, Semper paratus, LGST, Trust, Meeting, Acquisition, Business analyst

New York, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW, LGSTU), a publicly-traded special purpose acquisition company, announced today that its shareholders have approved the proposed business combination (the “Business Combination”) with Tevogen Bio Inc, a Delaware corporation (“Tevogen Bio”), at an extraordinary general meeting of Semper Paratus’ shareholders that was held on Wednesday, January 31, 2024 (the “Meeting”).

Key Points: 
  • New York, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW, LGSTU), a publicly-traded special purpose acquisition company, announced today that its shareholders have approved the proposed business combination (the “Business Combination”) with Tevogen Bio Inc, a Delaware corporation (“Tevogen Bio”), at an extraordinary general meeting of Semper Paratus’ shareholders that was held on Wednesday, January 31, 2024 (the “Meeting”).
  • Following the closing of the Business Combination, common stock of the combined company is expected to begin trading on Nasdaq under the symbol “TVGN”.
  • In connection with the Meeting, shareholders holding 1,432,457 shares out of a possible 1,502,180 Semper Paratus ordinary shares (the “Public Shares”) exercised their right to redeem their shares for a pro rata portion of the funds in Semper Paratus’ trust account (the “Trust Account”).
  • Following the Meeting, Semper Paratus’ Chief Executive Officer Surendra Ajjarapu stated “We have cleared yet another hurdle to closing our business combination with Tevogen Bio, and we will continue to work diligently with Tevogen Bio to satisfy the remaining closing conditions.”

Tevogen Bio Is Looking Forward to Closing Its Transaction With Semper Paratus

Retrieved on: 
Wednesday, January 31, 2024
Infectious Diseases, Pharmaceutical, Health, Oncology, Therapy, Virology, Medicine, Neurology, Semper paratus

Tevogen Bio Inc (“Tevogen Bio”) is looking forward to and continues to work toward the anticipated closing of its proposed business combination with Semper Paratus Acquisition Corporation.

Key Points: 
  • Tevogen Bio Inc (“Tevogen Bio”) is looking forward to and continues to work toward the anticipated closing of its proposed business combination with Semper Paratus Acquisition Corporation.
  • “Tevogen Bio’s business combination with Semper Paratus can help us achieve our goal to become the first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, and we look forward to investors having the opportunity to join us in this mission,” said Ryan Saadi, Chief Executive Officer of Tevogen Bio.
  • “We believe that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.”

Semper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on Nasdaq

Retrieved on: 
Wednesday, January 24, 2024
LGST, Business analyst, Semper paratus, Cayman Islands, Proxy, Plan, Acquisition, Sub

New York, NY, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW), a publicly-traded special purpose acquisition company, today announced that it has filed a supplement (“Prospectus Supplement”) to its definitive proxy statement/prospectus dated January 10, 2024 (the “Proxy Statement/Prospectus”) for the solicitation of proxies in connection with the extraordinary general meeting of Semper Paratus’ shareholders scheduled to be held on January 29, 2024, to consider and vote on, among other proposals as more fully set forth in the Proxy Statement/Prospectus, the transactions (collectively, the “Business Combination”) contemplated by that certain Agreement and Plan of Merger, dated June 28, 2023 (as it may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”), by and among Semper Paratus, Semper Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Semper Paratus (“Merger Sub”), Tevogen Bio Inc, a Delaware corporation (“Tevogen Bio”), SSVK Associates, LLC, a Delaware limited liability company, and Ryan Saadi in his capacity as seller representative (collectively, the “parties”), pursuant to which Semper Paratus will de-register from the Cayman Islands and redomesticate to the State of Delaware and change its name to Tevogen Bio Holdings Inc. (“New Tevogen”) and Merger Sub will merge with and into Tevogen Bio, with Tevogen Bio surviving as a wholly owned subsidiary of New Tevogen.

Key Points: 
  • New York, NY, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW), a publicly-traded special purpose acquisition company, today announced that it has filed a supplement (“Prospectus Supplement”) to its definitive proxy statement/prospectus dated January 10, 2024 (the “Proxy Statement/Prospectus”) for the solicitation of proxies in connection with the extraordinary general meeting of Semper Paratus’ shareholders scheduled to be held on January 29, 2024, to consider and vote on, among other proposals as more fully set forth in the Proxy Statement/Prospectus, the transactions (collectively, the “Business Combination”) contemplated by that certain Agreement and Plan of Merger, dated June 28, 2023 (as it may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”), by and among Semper Paratus, Semper Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Semper Paratus (“Merger Sub”), Tevogen Bio Inc, a Delaware corporation (“Tevogen Bio”), SSVK Associates, LLC, a Delaware limited liability company, and Ryan Saadi in his capacity as seller representative (collectively, the “parties”), pursuant to which Semper Paratus will de-register from the Cayman Islands and redomesticate to the State of Delaware and change its name to Tevogen Bio Holdings Inc. (“New Tevogen”) and Merger Sub will merge with and into Tevogen Bio, with Tevogen Bio surviving as a wholly owned subsidiary of New Tevogen.
  • The Prospectus Supplement was filed to revise the Proxy Statement/Prospectus to disclose that the parties have agreed to seek to list the New Tevogen common stock and public warrants on a tier of The Nasdaq Stock Market instead of the NYSE American, as previously disclosed in the Proxy Statement/Prospectus, and intend to proceed with the Business Combination on that basis.

Tevogen Bio Inc. and Semper Paratus Acquisition Corporation Announce Effectiveness of Registration Statement for Business Combination

Retrieved on: 
Friday, January 5, 2024
Virology, Business analyst, Acquisition, Form, Transaction, Special, Semper paratus, LGST, Therapy, Security (finance), Neurology

The pro forma equity value of the portion of the combined company attributable to Tevogen Bio Inc (“Tevogen Bio”) stockholders is an expected $1.2 billion.

Key Points: 
  • The pro forma equity value of the portion of the combined company attributable to Tevogen Bio Inc (“Tevogen Bio”) stockholders is an expected $1.2 billion.
  • Tevogen Bio is an advanced-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology.
  • New York, NY, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Inc (“Tevogen Bio”), an advanced-stage specialty immunotherapy biotech pioneer and Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW), a publicly-traded special purpose acquisition company, today announced that the Securities and Exchange Commission ("SEC") has declared effective the registration statement on Form S-4 (the "Registration Statement") filed by Semper Paratus in connection with Tevogen Bio and Semper Paratus’s previously announced proposed business combination (the “Business Combination” or the “Transaction”).
  • Semper Paratus will hold an extraordinary general meeting of its stockholders (the “Special Meeting”) at which shareholders will be asked to consider and vote upon proposals to approve the Business Combination and related matters.

Semper Paratus Acquisition Corporation Files Registration Statement on Form S-4 in Connection with Proposed Business Combination with Tevogen Bio Inc

Retrieved on: 
Thursday, September 14, 2023
Therapy, Semper paratus, Virology, Biotechnology, DSM-IV codes, Semper, Exchange, Infection, Medicine, Register, LGST, Prospectus, Acquisition, Transaction, Cancer, Registration statement, Form, Neurology, NYSE, Pharmaceutical industry, Security (finance)

The Registration Statement contains a preliminary proxy statement and prospectus in connection with the previously announced agreement and plan of merger (the “Merger Agreement”) and proposed business combination between Semper Paratus and Tevogen Bio (the “Transaction”).

Key Points: 
  • The Registration Statement contains a preliminary proxy statement and prospectus in connection with the previously announced agreement and plan of merger (the “Merger Agreement”) and proposed business combination between Semper Paratus and Tevogen Bio (the “Transaction”).
  • While the Registration Statement has not yet become effective and the information contained therein is subject to change, it provides important information about Tevogen Bio, Semper Paratus, and the Transaction.
  • Upon closing of the Transaction, the combined company will be named Tevogen Bio Holdings Inc. (“Tevogen Holdings”).
  • Tevogen Bio aspires to be the first biotechnology company offering commercially attractive, economically viable, and cost-effective personalized T cell therapies.

Tevogen Bio to Become Publicly Listed on NYSE via Business Combination with Semper Paratus Acquisition Corporation

Retrieved on: 
Thursday, June 29, 2023
Long COVID, Infection, Weapon, Antigen, Partnership, Therapy, Semper paratus, Virology, COVID-19, Clinical trial, Cancer, Semper, Multiple sclerosis, Immunotherapy, TVGN, LGST, Acquisition, Transaction, Viral, Cytotoxic T cell, Growth, Immunodeficiency, Health, MPH, Neurology, NYSE, Safety, Vaccine, Pharmaceutical industry, Management, MD

Tevogen Bio, along with its founder, has received broad recognition for its innovative, patient-first approach in the biopharma industry.

Key Points: 
  • Tevogen Bio, along with its founder, has received broad recognition for its innovative, patient-first approach in the biopharma industry.
  • Upon closing of the merger (the “Transaction”), the combined company will be named Tevogen Bio Holdings Inc. (“Tevogen Holdings”).
  • Tevogen Holdings common stock and warrants are expected to be listed on the NYSE under the new ticker symbol “TVGN”.
  • Additionally, the Transaction includes a contingent earnout in the form of additional equity in Tevogen Holdings payable to the Tevogen Bio stockholders and Semper Paratus’ sponsor.

Legion to Congress: Pay the Coast Guard!

Retrieved on: 
Tuesday, January 8, 2019
United States Coast Guard, Semper paratus, Semper, American Legion, Reistad, United States

"Senator John Thune has introduced the 'Pay Our Coast Guard Act," Reistad said.

Key Points: 
  • "Senator John Thune has introduced the 'Pay Our Coast Guard Act," Reistad said.
  • Citing the Coast Guard's Semper Paratus motto, Reistad said that The American Legion is "always prepared" to support the men and women in uniform.
  • "As a nonprofit, The American Legion is not capable of funding the entire Coast Guard payroll," Reistad said.
  • "But we are hoping that Americans immediately demand that Congress and the White House pay the Coast Guard.

Latest Edition of Coast Guard Outlook Magazine Released by Faircount in Print and Free Online Digital Edition

Retrieved on: 
Tuesday, January 8, 2019
United States Coast Guard, Coast guards, Military, Gendarmerie, Semper paratus, Commandant of the Coast Guard, Semper, United States, Safety

TAMPA, Fla., Jan. 8, 2019 /PRNewswire-PRWeb/ --Faircount Media Group has released the latest edition of Coast Guard Outlook dedicated to the pioneering Semper Paratus (Always Ready) spirit of the U.S. Coast Guard.

Key Points: 
  • TAMPA, Fla., Jan. 8, 2019 /PRNewswire-PRWeb/ --Faircount Media Group has released the latest edition of Coast Guard Outlook dedicated to the pioneering Semper Paratus (Always Ready) spirit of the U.S. Coast Guard.
  • This edition features our first interviews with Commandant of the U.S. Coast Guard Adm. Karl L. Schultz as well as Vice Commandant Adm. Charles W. Ray.
  • In addition to the coverage of Coast Guard leadership ideas and mission sets, we look at 75 years of Coast Guard helicopter flight, and 50 years of the U.S. Coast Guard's RDT&E arm.
  • To view the digital edition, sign up for the Coast Guard Outlook print edition and newsletter, please visit http://www.coastguardoutlook.com/digital-edition/ .

American Legion to Congress: Pay the Coast Guard!

Retrieved on: 
Monday, January 7, 2019
United States Coast Guard, Semper paratus, Semper, American Legion, Reistad, United States

"Senator John Thune has introduced the 'Pay Our Coast Guard Act,' " Reistad said.

Key Points: 
  • "Senator John Thune has introduced the 'Pay Our Coast Guard Act,' " Reistad said.
  • Citing the Coast Guard's Semper Paratus motto, Reistad said that The American Legion is "always prepared" to support the men and women in uniform.
  • "As a nonprofit, The American Legion is not capable of funding the entire Coast Guard payroll," Reistad said.
  • "But we are hoping that Americans immediately demand that Congress and the White House pay the Coast Guard.